Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28063493 | 1.00 | DPP4 (0.35) | DPP4SMN1; SMN2PIK3CD | |
| SCHEMBL16212051 | 1.00 | DPP4 (0.35) | DPP4SMN1; SMN2PIK3CD | |
| SCHEMBL15099989 | 0.83 | DPP4 (0.35) | DPP4SMN1; SMN2PIK3CD | |
| SCHEMBL17225491 | 0.80 | DPP4 (0.39) | DPP4SMN1; SMN2PIK3CD | |
| SCHEMBL20221842 | 0.79 | DPP4 (0.33) | DPP4 | |
| SCHEMBL27089326 | 0.76 | DPP4 (0.33) | DPP4 | |
| SCHEMBL27089331 | 0.76 | DPP4 (0.33) | DPP4 | |
| SCHEMBL3512916 | 0.75 | GRM2 (0.36) | DPP4 | |
| SCHEMBL6919995 | 0.75 | GRM2 (0.36) | DPP4 | |
| SCHEMBL4254372 | 0.75 | GRM2 (0.36) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415358-B | 6-aminopyridin-3-ylthiazoles as ROR gamma t modulators | 詹森药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-109851610-B | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | 赫普泰雅治疗有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| EP-3406609-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| WO-2017189661-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-02 | — | — | WO | disclosed |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3102568-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015118342-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | DPP4 2027/4885SMN1; SMN2 3501/4885PIK3CD 1542/4885 |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | DPP4 2067/4885SMN1; SMN2 3252/4885PIK3CD 1665/4885 |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | DPP4 2643/4885SMN1; SMN2 1525/4885PIK3CD 1865/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | DPP4 2027/4885SMN1; SMN2 3501/4885PIK3CD 1542/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | DPP4 2027/4885SMN1; SMN2 3501/4885PIK3CD 1542/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | DPP4 2643/4885SMN1; SMN2 1525/4885PIK3CD 1865/4885 |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | DPP4 2027/4885SMN1; SMN2 3501/4885PIK3CD 1542/4885 |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | DPP4 2067/4885SMN1; SMN2 3252/4885PIK3CD 1665/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | DPP4 2067/4885SMN1; SMN2 3252/4885PIK3CD 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.